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Abstract
Anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis is
considered a “pauci-immune” disease, characterized by absent or mild glomerular
tuft staining for immunoglobulin and/or complement.  We describe a 72-year-old
man with progressive renal failure over five months who was found to have 
P-ANCA associated crescentic glomerulonephritis. Renal biopsy also revealed
immunofluorescence staining for Immunoglobulin G and C3. Treatment comprised
corticosteroids, cyclophosphamide, and plasmapheresis but unfortunately kidney
function did not recover, likely due to substantial interstitial fibrosis at diagnosis.
This case illustrates that serologic evaluation for ANCAs should not be discounted
when immune deposits are present. Prompt diagnosis is warranted. 
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Introduction
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is
associated with rapidly declining renal function, and often leads to end-stage
renal disease (ESRD) or death if not treated promptly and aggressively [1].
The disease is typically characterized by “pauci-immune” cresentic
glomerulonephritis. However, there are a few reports of ANCA-associated
glomerulonephritis with immune deposits in the literature, and the exact
role of these deposits is not well understood [2-4]. 
Case report
A 72-year-old man with hypertension and chronic obstructive pulmonary
disease was referred to our institution for evaluation and management of
renal failure. He had been followed at an outside facility with progressively
deteriorating renal function over several months. Serum creatinine was 
1.6 mg/dl 5 months previously, and rose to 3.8 mg/dl in the next 3 months.
Initially, renal insufficiency was attributed to prostatic outlet obstruction.
However, renal function did not improve with attempts to relieve obstruction
by prostatectomy. Nephrotic-range proteinuria was also detected at 3.6 g 
of urinary protein per day. On presentation to our institution, physical
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examination demonstrated blood pressure 190/105
mmHg, bibasilar rales, and bilateral lower extremity
pitting edema. Initial pertinent laboratory results
included blood urea nitrogen (BUN) 50 mg/dl,
creatinine 7.2 mg/dl, positive ANCA by immuno  -
fluorescense (IF) of perinuclear or P-ANCA pattern and
titer of 1 : 80. Myeloperoxidase antibody was positive
but serine protease 3 antibody was negative. Urinalysis
showed microscopic hematuria. Renal biopsy revealed
active necrotizing crescentic glomerulonephritis with
focal segmental glomerulo  sclerosis, extensive tubular
atrophy and interstitial fibrosis (Figure 1A). Immu  -
nofluorescence demonstrated 2-3 + IgG immuno  -
globulin (Figure 1B) and C3 complement staining of the
capillary walls (Figure 1C). The patient was placed on
hemodialysis for management of volume overload and
azotemia. Given the active component of necrosis and
positive serum P-ANCA, he also received ten sessions
of plasmapheresis, cyclophosphamide 100 mg daily,
and methyl  prednisone 1 mg intravenously daily for
three days followed by oral prednisone 1 mg/kg daily.
Cyclophosphamide was reduced to 75 mg daily after
3 months and stopped at month 6. Prednisone was
tapered to 15 mg daily by month three, then to 7.5 mg
daily by month 6, and finally reduced by 1 mg daily
every 3 to 4 weeks to discontinuation. The patient
tolerated the treatment without complications, but
remained hemodialysis-dependant over the year of
follow-up.
Discussion
Anti-neutrophil cytoplasmic antibody was first
reported in 1982 by Davies et al. [5] in patients with
segmental necrotizing glomerulonephritis on biopsy
and absent or scant, irregular deposits by direct
immunoflorescence. The word “pauci” is derived from
Latin which means few, and the observation of
cresecentic glomerulo  nephritis with a paucity of IF
staining for immunoglobulins led to the original
definition of pauci-immune glomerulonephritis. 
Anti-neutrophil cytoplasmic antibody has since been
described as a characteristic serological marker of
small vessel vasculitides, including Wegener’s
granulomatosis, microscopic polyangitis, Churg-
Strauss syndrome and renal-limited vasculitis [6-8].
The pathophysiology underlying ANCA-associated
crescentic glomerulonephritis classically entails the
presence of auto-antibodies directed against certain
cytoplasmic components of circulating neutrophils
(myeloperoxidase or serine protease 3 antibodies) 
[9, 10]. In the glomerular tuft, antibody binding at the
endothelium leads to neutrophil activation, necrotizing
injury and inflammation; this also may occur in other
tiny vascular beds in the body. Active inflammation
is often followed by the development of fibro-cellular
and fibrous crescents. 
The clinical course of ANCA-associated glo  -
merulonephritis is characterized by insidious onset 
of hematuria and renal insufficiency. Systemic
involvement can occur and usually involves the skin,
lungs, musculoskeletal, and nervous systems. Rapid
decline in renal function is common, and delay in
diagnosis and treatment is associated with high risk
of ESRD or even death [1]. Prior to the introduction of
Figure 1. Biopsy specimen in the current case. (A) Light
microscopy showing active necrotizing and crescentic
glomerulonephritis, secondary focal and segmental
glomerulosclerosis, and extensive tubular atrophy
and interstitial fibrosis. (B) Immunofluorescence for
IgG demonstrating granular 2+ staining along
capillary walls. (C) Immunofluorescence for C3
showing granular 2-3+ deposits along capillary walls
A
B
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immunosuppressive treatments, median survival with
pauci-immune vasculitis was 5 months [11], but
survival steadily improved with the introduction of
immunosuppressive agents.  In the early 1970s, Fauci
et al. [12] introduced cyclophosphamide in com  -
bination with corticosteroids as an effective treatment
for pauci-immune vasculitis and observed a complete
remission rate of 75%. Recent studies suggest that
azathioprine may be as effective as cyclophosphamide
in inducing remission of ANCA-medicated vasculitis
[13, 14]. However, the prognosis for patients with
significant renal injury is distinctly poor.
Plasmapheresis has been increasingly adopted as
adjunctive therapy for rapidly progressive ANCA-
associated glomerulonephritis [15]. A recent ran  -
domized controlled trial confirmed the efficacy of
plasma exchange, demonstrating a 24% absolute
reduction in the risk of progression to ESRD at 
12 months, from 43% to 19%, compared to intravenous
methylprednisolone (in addition to cyclophosphamide
and prednisone for all patients) [16]. In our case,
plasmapheresis was attempted along with
immunosuppressive agents based on the presence
of active necrotizing crescents on renal biopsy
findings, and the patient tolerated the therapy
without major adverse events. Unfortunately, he
remained dialysis-dependent, likely because the
process had progressed to yield substantial interstitial
fibrosis by the time of diagnosis and treatment. 
Although ANCA-associated glomerulonephritis is
classically pauci-immune, our case demonstrated IF
Author Cases (n)C a ses with positive  Management Outcomes data (IF positive vs. negative)
IF (Ig), and degree 
of positivity
Neumann  37 6 (IgM, IgA), CP, P Ig deposition associated 
et al. [4]  1 (IgG, C3), ≥ 2+ with more proteinuria (5.4 ±3.1 vs. 1.3 ±1.0 g/24 h;
p = 0.016) and a non-significant trend 
towards worse renal survival
Lanham   5 4 (Ig M, C3), P and/or CP, AZT  Rapid initial response in all cases. Only one case 
et al. [17] 1 (IgA) developed significant renal failure that was
successfully reversed with treatment
Vrtovsnik  1 1 (IgA) Pulse CP, P NR
et al. [18] 
Andrassy  25 2 (IgA), “mild-to- P for 9 months after NR
et al. [19] moderate” deposits  clinical remission and CP
(with uromitexan) for 
2 years after remission,
followed by either AZT 
or termination of 
treatment
Brouwer 20 7  (IgM) NR NR
et al. [20] 10  (C3)
Grotz   1 10 (C3, IgM, IgG,  CP, P (13 patients) and NR
et al. [21] or IgA) plasma exchange
(9 patients)
Ronco    41 3 (IgG, IgM),  P, CP (20 patients),  NR
et al. [22] 2 (IgA), 12 (C3);   P (29 patients), AZT 
“significant” (2 patients), 
deposits plasmapheresis 
(2 patients)
Hu   2 2 (IgG, IgA, IgM,  P  NR
et al. [23] and/or C3)
Pinching  13 8 (IgG),  P, CP and/or plasma- Reversal of renal failure with combination therapy
et al. [24]  5 (IgM), pheresis for initial control
12 (C3) of fulminant cases
Haas  126 68 (IgM, IgG, IgA, CP and corticosteroid Ig deposition associated with higher median
et al. [2] C3 and/or C1q) proteinuria (3.2 vs. 1.3 g/24 h, p < 0.0001),
and a non-significant trend towards higher serum
creatinine 
CP – cyclophosphamide, P – predinisolone, AZT – azathioprine, IF – immunofluorescence, Ig – immunoglobulin, NR – not reported
Table I. Summary of published cases of “pauci-immune” glomerulonephritis with immune deposits and clinical
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staining for IgG and C3 deposits. We searched 
the MEDLINE/PubMed electronic database for
publications on ANCA-associated glomerulonephritis
with IF staining published in English language from
1983 to 2009 using the MeSH terms “ANCA”,
“glomerulonephritis”, and “immune deposits”. The
search yielded ten relevant articles that comprised
case reports and small case series (Table I). Among
281 biopsies that were described in patients with
ANCA-associated glomerulonephritis, 154 biopsies
(54%) showed positive IF for IgG, IgM, IgA, and/or
complements.  The proportion of biopsies with heavy
staining could not be ascertained as the degree of
positivity was not reported for all cases. In general,
the patients were treated with corticosteroids and
cyclophosphamide, and some received plasma  -
pheresis.  The majority of the cases showed good
response to these regimens. Neumann et al. [4] and
Haas and Eustace [2] observed significantly heavier
proteinuria and trends towards worse renal function
in the subsets with immune deposits.
The patholophysiologic role of immune deposits
in patients with ANCA-mediated vasculitis is
unclear. The hypothesis that immune complexes
act synergistically with ANCA to produce more
severe glomerulonephritis, as manifest by heavier
proteinuria and inferior kidney function, was raised
by some authors [2, 4]. There are also reports of
predominant mesangial IgA deposits described as
concomitant ANCA-associated glomerulonephritis
and IgA nephropathy [3, 18]. Findings from several
animal studies have lead to the notion that early
immune complex deposition may play a role in the
initiation of vasculitis and glomerulonephritis 
[25, 26]. A transient immune deposit was observed
in an animal model of ANCA-associated glomerulo  -
nephritis following injection of rats with myelo  -
peroxidase [25]. In some models, it was postulated
that immune complex deposits disappeared before
tissue biopsy was performed.
In conclusion, immune deposits may be found in
a subset of patients with ANCA-associated 
glo  merulonephritis. Anti-neutrophil cytoplasmic
antibody-associated glomerulo  nephritis is an
aggressive disease that warrants prompt diagnosis
and treatment. It is important to test for serological
markers such as ANCA even in cases with active IF
and immune deposits on renal histology. Cases such
as ours also raise the question of whether 
ANCA-associated glomeru  lonephritis is truly pauci-
immune. Perhaps, deposits that appear early in the
disease process are commonly degraded, or the
observation may represent an overlap of two
disease forms. Additional studies are warranted to
further understand the definitive role and best
treatment of patients with ANCA-associated
glomerulo  nephritis and immune deposits.
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